Selection of blockbuster announcements

1、$XPeng Inc.-W (09868.HK) $Revenue in the first quarter was 7.45 billion yuan, an increase of 152.6% over the same period last year

XPeng Inc. 's total income in the first quarter was 7.4549 billion yuan, an increase of 152.6% over the same period last year. The adjusted net loss was 1.528 billion yuan, compared with 696 million yuan in the same period last year. XPeng Inc. expects second-quarter revenue of 6.8 billion yuan to 7.5 billion yuan, while the market is expected to be 8.33 billion yuan. XPeng Inc. 's total car delivery reached 34561 in the first quarter, an increase of 159% over the same period last year; delivery is expected to be 3.1-34000 in the second quarter.

2、$Junshi creature (01877.HK) $Early treatment of VV116: mild to moderate COVID-19 phase III registered clinical study reached the main end point

Junshi Bio issued an announcement. The company's holding subsidiary Shanghai Juntuo Biopharmaceutical Technology Co., Ltd. and Suzhou Wangshanwang Water Biomedicine Co., Ltd. developed oral nucleoside anti-SARS-CoV-2 drug VV116 tablets (project code: JT001/VV116) in a phase III registered clinical study (NCT05341609) compared with Naimativir tablets ╱ ritonavir tablets (i.e. PAXLOVID) for early treatment of mild to moderate COVID-19. The company will communicate with the regulatory authorities in the near future to submit applications for the listing of new drugs.

3、Shanghai Petrochemical Company Limited (00338.HK) $The actual controller, China Petroleum & Chemical Group, increases its stake by 10 million shares.

Shanghai Petrochemical Co., Ltd. announced that the company received notice from Petrochina Chemical Group Co., Ltd., the actual controller of the company, on May 23, 2022. China Petroleum & Chemical Group, through its wholly-owned subsidiaries abroad, increased its holdings of 10 million H shares in the secondary market, accounting for about 0.1 per cent of the total issued shares of the company.

4、$Sino Biopharmaceutical (01177.HK) $The anti-tumor class I innovative drug "TQ-B3139" is declared to be on the market.

Sino Biopharmaceutical announced that the anti-tumor class I innovative drug "TQ-B3139" developed by the group has been listed and accepted by the State Drug Administration of China. The indication of this declaration is the treatment of locally advanced or metastatic non-small cell lung cancer patients with positive anaplastic lymphoma kinase. The product specifications are 100mg, 125mg and 150mg.

5、$Tencent (00700.HK) $It is proposed to issue 10.0985 million new shares under the share incentive scheme

Tencent: on May 23, 2022, the board of directors resolved to issue a total of 10.0985 million new shares in accordance with the general authority granted by the shareholders of the Company at the annual general meeting of 2022 (the maximum number of shares that may be issued and allotted is 1.922 billion shares). A total of 9.8104 million award shares will be issued in accordance with the 2019 plan for the awards granted to not less than 7000 rewards in July 2011. And a total of 288100 additional award shares were issued for the above-mentioned projects in accordance with the adjustments made as a result of in-kind distribution.

Financial report information

XPeng Inc.-W (09868) first quarter revenue of 7.45 billion yuan increased by 152.6% compared with the same period last year.

Merger and acquisition and sale

Delin Holdings (01709) intends to acquire 45% stake in Delin Family Office in Hong Kong and HK $15.5 million to acquire all shares in Anrui Wealth.

MSDH (02138) intends to acquire Hong Kong physical examination business with HK $41.25 million.

China Water Industry Group (01129) plans to acquire all shares of Taiyuan Yuantong by 13.55 million yuan.

Sanbao Technology (01708): the reserve price of 15.1236% equity transfer of Xin Investment Company is 41.2632 million yuan.

Increase and decrease holdings

Shanghai Petrochemical Co., Ltd. (00338). China Petroleum & Chemical Group increases its stake by 10 million shares.

Investment and operation

China International Marine Containers (02039): Singapore Raffles, Southern CIMC and Yantai Guofeng Group formally signed a "joint venture contract"

Sino Biopharmaceutical (01177): anti-tumor Class I innovative drug "TQ-B3139" declared and listed on the market

Aoneng Construction (01183): issue dividend warrants to be listed on the main board of the Stock Exchange

China Merchants Bank (03968): China Merchants Bank completed capital increase, stock expansion and change of registered capital.

Junshi Bio (01877): VV116 compared with PAXLOVID in the early treatment of mild to moderate COVID-19 phase III registered clinical trial reached the main end point.

Repurchase cancellation

AIA Group Limited (01299) spent HK $162 million to buy back 2.06 million shares on May 23.

Sunac Services (01516) spent HK $19.2505 million to buy back 5 million shares on May 23.

Haier Smart Home (06690) spent 87.554 million yuan to buy back 3.4227 million A shares on May 23.

JD Health (06618) spent HK $18.3821 million to buy back 389400 shares on May 23.

CANSINOBIO-B (06185) spent 13.8352 million yuan to buy back 86100 A shares on May 23.

Equity incentive

The overseas Chinese City Light and luxury Institute achieved its profit target, and the Aidi Palace (00286) awarded Zhu Yufei 30 million award shares.

Tencent (00700): plans to issue 10.0985 million new shares under the share incentive scheme

Sino Biopharmaceutical (01177): the trustee further purchased 4.725 million shares

Debt financing

Poly property Group (00119) received a revolving loan of US $100 million from the bank.